

Non-Hodgkins lymphoma T-cell protocol

Submission date 01/07/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 23/02/2015	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

NHL9503

Study information

Scientific Title

Non-Hodgkins lymphoma T-cell protocol

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

Interventions

1. Group A: Chemotherapy including third intensification block at 35 weeks
2. Group B: Chemotherapy without third intensification block at 35 weeks

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1997

Completion date

28/02/2000

Eligibility

Key inclusion criteria

1. T-cell non-Hodgkin's lymphoma
2. Stages I-IV
3. Confirmed remission achieved
4. Less than 25% blasts in bone marrow
5. No circulating blasts in blood
6. Aged <18 years

Participant type(s)

Patient

Age group

Child

Upper age limit

18 Years

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Patients with T-cell anaplastic lymphoma or peripheral T-cell lymphoma are excluded.

Date of first enrolment

01/01/1997

Date of final enrolment

28/02/2000

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type

Charity

Website

<http://www.cancer.org.uk>

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

United Kingdom Children's Cancer Study Group (UKCCSG)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration